The bacterial extract OM-85 BV protects mice against influenza and Salmonella infection.
The bacterial extract OM-85 BV has been shown to provide protection against recurrent respiratory infections. We here investigated its efficacy against viral and bacterial infections in murine models. We first evaluated the role of OM-85 BV protecting from an A/PR/8/34 (H1N1) influenza virus infection. In a group treated with 1.75 mg/mouse OM-85 BV all animals survived, compared to 70% in the untreated control group and a group treated with a lower dosage. In addition, the appearance of clinical signs was delayed, their intensity was decreased, and they disappeared faster; also a marked increase in the influenza hemagglutination inhibition antibody level was observed. Since bacterial infections often superimpose viral lung infections, we also investigated on the protection of mice from a Salmonella typhimurium infection after the oral administration of OM-85 BV. Here, 100% of the OM-85 BV treated animals survived compared to 58% of the untreated control group. The mechanism of protection was further investigated: OM-85 BV acts, on the one hand, as an immunogen: the repeated administration of OM-85 BV induced a marked increase in serum antibody levels recognizing pathogenic bacterial strains. On the other hand, the extract acts as a stimulator of the nonspecific macrophage, monocyte, dendritic cell, and granulocyte response. Our findings demonstrate the antimicrobial activity of OM-85 BV against infections, as also has been shown in clinical studies.
Bessler
Wolfgang G
WG
Institute for Molecular Medicine and Cell Research, University Clinic, Freiburg, Germany. wolfgang.bessler@mol-med.uni-freiburg.de
Vor dem Esche
Ulrich
U
Masihi
Noel
N
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D001170:Arthritis, Infectious / Q000097:blood; D001419:Bacteria; D002457:Cell Extracts / Q000627:therapeutic use*; D003713:Dendritic Cells / Q000187:drug effects / Q000276:immunology; D004195:Disease Models, Animal; D006098:Granulocytes / Q000187:drug effects / Q000276:immunology; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype; D007251:Influenza, Human / Q000517:prevention & control*; D008171:Lung Diseases / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D008264:Macrophages / Q000187:drug effects / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D009000:Monocytes / Q000187:drug effects / Q000276:immunology; D012480:Salmonella Infections / Q000517:prevention & control*; D012486:Salmonella typhimurium / Q000187:drug effects / Q000276:immunology; D000095983:Bacterial Lysates
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D002457:Cell Extracts; C030259:Broncho-Vaxom; D000095983:Bacterial Lysates